How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...
RXRX is trading in the middle of its 52-week range and near its 200-day simple moving average. Price change The price of RXRX shares has increased $0.02 since the market last closed. This is a 0.57% ...
Unlike many bulk-generated skill repositories, this collection focuses on real-world Agent Skills created and used by actual engineering teams, not mass AI‑generated stuff. Compatible with Claude Code ...
Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Recursion Pharmaceuticals reported 2 insider transactions totaling $97,222.74. Activity consisted of 1 tax payment of $18,400.36 and 1 sale of $78,822.38. Average transaction value was $48,611.37 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results